Drug intelligence / Profile preview

LK-02

Development stage: Preclinical
Lead developer: LiveKidney.Bio
Modality: Hydrogel Systems → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies
Administration: Perirenal Adipose Tissue Injection

Overview

LK-02 is a mesenchymal stromal cell (MSC)-based cell therapy being developed by LiveKidney.Bio for the treatment of kidney disease in patients with metabolic syndrome. The therapy utilizes proprietary hydrogel-based formulations of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) designed for the continuous release of therapeutic bioactive compounds. LK-02 is administered via a unique route of injection into the perirenal adipose tissue (PRAT). The mechanism of action involves modulating the immune system, reducing inflammation and fibrosis, and improving mitochondrial activity to enhance kidney function and address hallmarks of aging.

Beyond the preview

Go deeper on LK-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LK-02.

Explore the full profile